
Opinion|Videos|May 7, 2025
Advanced Treatment Options in Parkinson Disease
Panelists discuss how physicians typically consider advanced Parkinson disease treatments when conventional therapies fail to adequately control motor fluctuations, highlighting challenges such as adverse effects, device-related complications, and patient selection criteria.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Advanced Treatment Considerations and Challenges
Timing for Advanced Treatment Consideration:
- When standard oral medications fail to adequately control motor fluctuations
- When optimal oral therapy causes intolerable adverse effects
- When quality of life is significantly impacted despite medication optimization
- Usually 5 to 10 years into disease course
- When off time exceeds 2 hours daily despite optimization
Challenges With Current Treatment Options:
- Narrow therapeutic window of levodopa (balancing efficacy vs dyskinesias)
- Pharmacokinetic limitations of oral medications
- Gastrointestinal dysfunction affecting medication absorption
- Cognitive decline limiting complex medication regimens
- Peripheral adverse effects (orthostasis, nausea, impulse control disorders)
- Patient adherence to complex regimens
- Surgical interventions: patient selection criteria, resource limitations, expertise availability
- Cost and insurance coverage barriers for advanced therapies
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease
2
Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited
3
Apomorphine Sublingual Film Displays Efficacy in Elderly Patients with Parkinson Disease
4
Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)
5









































